Jenburkt Pharmaceuticals Ltd. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 134395,
    "name": "Jenburkt Pharma",
    "stock_name": "Jenburkt Pharma",
    "full_name": "Jenburkt Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/jenburkt-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,179.80",
    "chg": 30.9,
    "chgp": "2.69%",
    "dir": 1,
    "prev_price": "1,148.90",
    "mcapval": "520.68 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524731,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE354A01013",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "913 ",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4000004",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_technicaldot_4000004.png",
        "date": "2026-05-20 08:00:21",
        "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum. After a period of mild bearishness, the stock’s technical indicators now suggest a sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. This article analyses the latest technical parameters, price momentum, and relative performance against the broader market to provide a comprehensive view for investors."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3997682",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_technicaldot_3997682.png",
        "date": "2026-05-19 08:00:26",
        "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum. After a period of sideways movement, the stock’s technical parameters now indicate a mildly bearish trend, reflecting a complex interplay of bullish and bearish signals across key indicators such as MACD, RSI, Bollinger Bands, and moving averages. This article analyses these technical developments in detail, contextualising them within the stock’s recent price action and broader market performance."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3986243",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_technicaldot_3986243.png",
        "date": "2026-05-12 08:00:29",
        "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects."
      },
      {
        "title": "Jenburkt Pharmaceuticals Gains 11.59%: 3 Key Factors Driving the Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-gains-1159-3-key-factors-driving-the-surge-3984316",
        "imagepath": "",
        "date": "2026-05-10 16:01:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Week opens at Rs.1,042.20</p>\n                    <p><strong>6 May:</strong> Q4 FY26 results reveal margin expansion</p>\n                    <p><strong>7 May:</strong> Technical momentum shift and valuation upgrade</p>\n                    <p><strong>8 May:</strong> Week closes at Rs.1,162.95 (-0.58% on day)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,042.20</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,162.95</div><div class=\"stat-change positive\">+11.59%<..."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. Exhibits Technical Momentum Shift Amid Strong Price Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-exhibits-technical-momentum-shift-amid-strong-price-gains-3978598",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_technicaldot_3978598.png",
        "date": "2026-05-07 08:00:18",
        "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a 7.11% gain in the stock price on 7 May 2026, reflecting renewed investor interest and a potential inflection point in its price trajectory."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd: Valuation Shift Signals Price Attractiveness Change",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-valuation-shift-signals-price-attractiveness-change-3978574",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_valuationdot_3978574.png",
        "date": "2026-05-07 08:00:06",
        "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, reflects evolving market perceptions and invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks."
      },
      {
        "title": "Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jenburkt-pharmaceuticals-ltd-latest-results-good-or-bad-3978370",
        "imagepath": "",
        "date": "2026-05-06 19:15:07",
        "description": "Jenburkt Pharmaceuticals Ltd. has reported its financial results for Q4 FY26, showcasing notable operational trends. The company achieved net sales of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% from ₹43.02 crores in Q3 FY26, and an 8.72% increase compared to ₹41.05 crores in Q4 FY25. This modest revenue growth is complemented by a significant improvement in profitability, with net profit reaching ₹10.85 crores, which is an 82.97% increase from the previous quarter's ₹5.93 crores.\n\nA key highlight of the quarter was the operating margin, which surged to 31.93%, up from 17.25% in Q3 FY26. This substantial margin recovery, representing a 1,468 basis point expansion, was primarily driven by a significant reduction in employee costs, which decreased from ₹14.71 crores to ₹9.52 crores. The improvement in operational efficiency is further evidenced by the operating profit before depreciation, i..."
      },
      {
        "title": "When is the next results date for Jenburkt Pharmaceuticals Ltd.?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-jenburkt-pharmaceuticals-ltd-3969170",
        "imagepath": "",
        "date": "2026-04-29 23:16:07",
        "description": "The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for 05 May 2026...."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3958962",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/JenburktPharmac_mojoScore_3958962.png",
        "date": "2026-04-23 10:10:41",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 15,
    "sid": "134395",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/jenburkt-pharmaceuticals-134395"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "27-May-2026",
      "details": "Newspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "07-May-2026",
      "details": "Annual Secretraial Compliance Report for the financial year ended 31st March 2026.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Record Date And Cut-Off Date",
      "datetime": "06-May-2026",
      "details": "The Company has fixed Friday 28th August 2026 as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during the 41st AGM.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jenburkt Pharmaceuticals Ltd. has declared <strong>180%</strong> dividend, ex-date: 11 Jul 25",
          "dt": "2025-07-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-05-20 08:00:21

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum. After a period of mild bearishness, the stock’s technical indicators now suggest a sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. This article analyses the latest technical parameters, price momentum, and relative performance against the broader market to provide a comprehensive view for investors.

Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-05-19 08:00:26

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum. After a period of sideways movement, the stock’s technical parameters now indicate a mildly bearish trend, reflecting a complex interplay of bullish and bearish signals across key indicators such as MACD, RSI, Bollinger Bands, and moving averages. This article analyses these technical developments in detail, contextualising them within the stock’s recent price action and broader market performance.

Jenburkt Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-05-12 08:00:29

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects.

Jenburkt Pharmaceuticals Gains 11.59%: 3 Key Factors Driving the Surge

2026-05-10 16:01:01

Key Events This Week 4 May: Week opens at Rs.1,042.20 6 May: Q4 FY26 results reveal margin expansion 7 May: Technical momentum shift and valuation upgrade 8 May: Week closes at Rs.1,162.95 (-0.58% on day) Week OpenRs.1,042.20 Week CloseRs.1,162.95+11.59%<...

Jenburkt Pharmaceuticals Ltd. Exhibits Technical Momentum Shift Amid Strong Price Gains

2026-05-07 08:00:18

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a 7.11% gain in the stock price on 7 May 2026, reflecting renewed investor interest and a potential inflection point in its price trajectory.

Jenburkt Pharmaceuticals Ltd: Valuation Shift Signals Price Attractiveness Change

2026-05-07 08:00:06

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, reflects evolving market perceptions and invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks.

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

2026-05-06 19:15:07

Jenburkt Pharmaceuticals Ltd. has reported its financial results for Q4 FY26, showcasing notable operational trends. The company achieved net sales of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% from ₹43.02 crores in Q3 FY26, and an 8.72% increase compared to ₹41.05 crores in Q4 FY25. This modest revenue growth is complemented by a significant improvement in profitability, with net profit reaching ₹10.85 crores, which is an 82.97% increase from the previous quarter's ₹5.93 crores. A key highlight of the quarter was the operating margin, which surged to 31.93%, up from 17.25% in Q3 FY26. This substantial margin recovery, representing a 1,468 basis point expansion, was primarily driven by a significant reduction in employee costs, which decreased from ₹14.71 crores to ₹9.52 crores. The improvement in operational efficiency is further evidenced by the operating profit before depreciation, i...

When is the next results date for Jenburkt Pharmaceuticals Ltd.?

2026-04-29 23:16:07

The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for 05 May 2026....

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-04-23 10:10:41

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

View All News